1. Home
  2. TCMD vs EVO Comparison

TCMD vs EVO Comparison

Compare TCMD & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactile Systems Technology Inc.

TCMD

Tactile Systems Technology Inc.

HOLD

Current Price

$23.44

Market Cap

514.9M

Sector

Health Care

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.53

Market Cap

568.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCMD
EVO
Founded
1995
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
514.9M
568.6M
IPO Year
2016
2007

Fundamental Metrics

Financial Performance
Metric
TCMD
EVO
Price
$23.44
$1.53
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
★ $37.67
$4.23
AVG Volume (30 Days)
★ 167.8K
83.4K
Earning Date
11-02-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 17.14
N/A
EPS
★ 0.26
N/A
Revenue
N/A
N/A
Revenue This Year
$9.98
N/A
Revenue Next Year
$9.44
$20.47
P/E Ratio
$91.00
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.84
$1.33
52 Week High
$37.77
$4.19

Technical Indicators

Market Signals
Indicator
TCMD
EVO
Relative Strength Index (RSI) 56.49 45.54
Support Level $22.92 $1.50
Resistance Level $27.67 $1.97
Average True Range (ATR) 0.60 0.05
MACD 0.18 0.02
Stochastic Oscillator 81.96 60.73

Price Performance

Historical Comparison
TCMD
EVO

About TCMD Tactile Systems Technology Inc.

Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: